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Abstract: Background: There is increasing evidence that marine omega-3 oils are involved in the
reduction of cancer risk and progression. However, the anticancer effect of omega-3 monoglyceride
on colorectal cancer has yet to be assessed. The goal of this study was to evaluate the anti-cancer
effects of eicosapentaenoic acid monoglyceride (MAG-EPA) in HCT116 colorectal carcinoma cells.
Methods: The effect of MAG-EPA was evaluated in vitro on HCT116 cells and in vivo on mouse
model of HCT116 xenograft. Results: Our data reveal that MAG-EPA decreased cell proliferation
and induced apoptosis in HCT116 cells. In a xenograft mouse model, daily per os administration of
MAG-EPA reduced tumor growth. Furthermore, MAG-EPA treatments decreased EGFR, VEGFR, and
AKT activation pathways and reduced VEGF and HIF1α expression levels in tumors. Conclusion:
MAG-EPA may promote apoptosis and inhibit growth of tumors by suppressing EGFR and VEGFR
activation pathways. Altogether, these data provide new evidence regarding the mode of action of
MAG-EPA in colorectal cancer cells.
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1. Introduction
At the present time, approximately 60% of approved cancer treatment drugs are of natural
origin [1]. An estimated 14,000 pharmacologically active compounds have been isolated from marine
plants and animals, showing the immense diversity found within this environment. These marine
natural products or bioactive compounds may inhibit one or more stages of carcinogenesis by
preventing development or treating cancer [1,2]. Among major marine compounds known to display
anti-inflammatory and anti-cancer effects, omega 3 polyunsaturated fatty acids (omega 3 PUFAs) are
likely the most studied [2,3]. Omega-3 polyunsaturated fatty acids (PUFAs) are essential for human
health and are found primarily in coldwater fish in the form of eicosapentaenoic acid (EPA; 20:5n-3)
and docosahexaenoic acid (DHA; 22:6n-3) [1,4]. In order to obtain an efficient dose and health beneficial
effects, various formulations of omega 3 PUFA supplements are available, such as free fatty acids,
ethyl esters, triacylglycerides, phospholipids, and monoacylglycerides.
Studies have shown that omega 3 fatty acids in monoacylglyceride forms did not required
pancreatic lipase to be absorbed by the gastro intestinal tract: this property confers increased
absorption, and thus a higher bioavailability when compared to other formulations [5–8]. Moreover,
pharmacokinetic analyses clearly demonstrated that MAG-DHA increases the bioavailability of DHA
compared to triacylglyceride (DHA-TG) or DHA ethyl ester (DHA-EE) [6,7]. Our previous study has
shown a better absorption of omega 3 PUFA monoacylglycerides in cultured human colorectal cancer
cells when compared to the absorption rate of the corresponding free PUFA [8]. Colorectal cancer
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(CRC) is the second most common cause of cancer mortality [9]. Diet factors and nutritional disorders
also play important roles in tumorigenesis and tumor development [4]. Despite the emergence of
new targeted agents and the use of various therapeutic combinations, none of the treatment options
available are curative in patients with advanced CRC [9]. The aim of this study was to determine
the anti-cancer effects of eicosapentaenoic acid monoglyceride (MAG-EPA). The specific objective
was to evaluate the effect of MAG-EPA on tumor growth and VEGFR and EGFR activation pathways
using an in vitro model of human colorectal cancer cell line HCT116 and an in vivo mouse model of
HCT116 xenograft.
2. Results
2.1. Effect of n-3 PUFA Monoglyceride Treatments on Cell Proliferation and Apoptosis in HCT116 Cells
The effect of MAG-EPA treatments was evaluated on growth inhibition in human HCT116 cells.
The cells were treated with increasing concentrations of MAG-EPA (0.01 µM, 0.03 µM, 0.1 µM,
0.3 µM, 1 µM, 3 µM, 10 µM, 30 µM and 100 µM) and counted using a Countess Automated Cell
Counter. Cumulative concentration response curves (CCRC) are illustrated on Figure 1a, and
results demonstrated that MAG-EPA reduced cell growth of HCT116 cells, with an IC50 value
of 1.32 ± 0.05 µM (Figure 1a). BrdU assay was performed to evaluate the effect of incremental
concentrations of MAG-EPA on cell proliferation rate. CCRC revealed that MAG-EPA significantly
reduced the HCT116 cell proliferation, with IC50 value of 1.25 ± 0.03 µM (Figure 1b). TUNEL assay
was performed to determine the ability of MAG-EPA to induce apoptosis in HCT116 cells. Data
revealed that 1 µM, 3 µM, 10 µM and 30 µM MAG-EPA induced apoptosis of HCT116 cells in a
concentration-dependent manner (Figure 1c). Moreover, we performed an ELISA assay to evaluate the
effect of MAG-EPA on caspase-3 activation. Figure 1d showed that 1 µM, 3 µM, 10 µM and 30 µM of
MAG-EPA induced activation of caspase 3 in HCT116 cells (Figure 1d).
2.2. Effect of MAG-EPA on HCT116 Spheroids Proliferation and Apoptosis
Light microscopy was used to determine the volume of spheroids (4/3·pi·r3) in control and after
treatment with MAG-EPA. Results indicate that following 48 h of a 3 µM and 10 µM MAG-EPA
treatments, the volumes of HCT116 spheroids were significantly decreased (0.093 ± 0.013 mm3
and 0.061 ± 0.008 mm3, respectively) when compared to control spheroids (0.134 ± 0.011 mm3)
(Figure 2a). MAG-EPA treatment was evaluated on spheroids proliferation following Cyquant assay.
Quantitative analyses on Figure 2b revealed that 1 µM, 3 µM, 10 µM and 30 µM MAG-EPA decreased
the proliferation rate of HCT116 cells in a concentration-dependent manner. Immunofluorescence
staining using a specific antibody against cleaved caspases 3 and 7 was performed on HCT116
spheroids derived from control (untreated) and from 30 µM MAG-EPA-treated spheroids. In these
spheroids, a 48 h treatment with 30 µM MAG-EPA consistently increased cleaved caspases 3 and
7 staining when compared to control (untreated) HCT116 spheroids (Figure 2c). Quantitative analysis
demonstrated a significant increasing in cleaved caspases 3 and 7 in cells derived from 1 µM, 3 µM,
10 µM and 30 µM MAG-EPA-treated spheroids when compared to control (untreated) spheroids
(Figure 2d).
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Figure 1. Effect of eicosapentaenoic acid monoglyceride (MAG-EPA) treatments on growth, 
proliferation and apoptosis levels in HCT116 cells. (a) Cumulative concentration response curves 
(CCRC) displaying the growth inhibitory effect induced by MAG-EPA in HCT116 cells (n = 8 for each 
experimental condition). (b) CCRC showing the MAG-EPA inhibitory effect on proliferation of 
HCT116 following BrdU assay (n = 6). (c) Bar histogram displaying the apoptotic index calculated 
following TUNEL assay for HCT116 cells in control and treated with 1 μM, 3 μM, 10 μM and 30 μM 
MAG-EPA (n = 6 for each experimental condition * p < 0.05). (d) Mean cleaved caspase 3 activity was 
determined using specific ELISA on cell lysates derived from control and MAG-EPA-treated cells  
(n = 6 * p < 0.05). 
Figure 1. Effect of eicosapentaenoic acid monoglyceride (MAG-EPA) treatments on growth,
proliferation and apoptosis levels in 116 cells. (a) u ulative concentration response curves
(CCRC) displaying the gro th inhibitory effect induced by -EP in CT116 cells (n = 8 for each
experi ental condition). (b) CCRC showing the MAG-EPA inhibitory effect on proliferation of HCT116
following BrdU assay (n = 6). (c) Bar histogram displaying the apoptotic index calculated following
TUNEL assay for HCT116 cells in control and treated with 1 µM, 3 µM, 10 µM and 30 µM MAG-EPA
(n = 6 for each experimental condition * p < 0.05). (d) Mean cleaved caspase 3 activity was determined
using specific ELISA on cell lysates derived from control and MAG-EPA-treated cells (n = 6 * p < 0.05).
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Figure 2. Effect of MAG-EPA on HCT116 cell proliferation and apoptosis in spheroid culture.  
(a) Volume of control and MAG-EPA-treated spheroids, n = 15 for each experimental condition,  
* p < 0.05. (b) Bar histogram displaying inhibitory effect of MAG-EPA on spheroids proliferation 
following Cyquant assay, n = 12 for each condition. (c) Cleaved caspases 3 and 7 signals in HCT116 
spheroids in control and following 48 h MAG-EPA treatment (30 μM). Green, caspase 3/7; blue, 
nuclear DNA (DAPI). Bar 100 μm. (d) Mean caspase 3/7 activity was determined using the cell event 
fluorometric assay on control and MAG-EPA-treated HCT116 spheroids, n = 12. 
2.3. MAG-EPA Treatment Reduced HCT116-Induced Tumor Formation 
To determine the ability of MAG-EPA to reduce tumor formation an in vivo HCT116 xenograft 
model was used. Following the formation of 100 mm3 tumors, the mice were randomly divided into 
two groups at day 13, namely control and MAG-EPA-treated. Mice received MAG-EPA per os daily 
at a pharmacological dose of 618 mg/kg corresponding to a daily omega-3 dose of 3 g for humans 
(Health Canada fish oil monograph), following dose translation of human to mouse by the equation 
described by Reagan-Shaw [10]. Results revealed that the MAG-EPA treatment was able to arrest 
tumor growth and reduce the size of the tumor observed prior to treatment (Figure 3a). Moreover, at 
day 13, the mean tumor volume was 101.7 ± 2.6 mm3, whereas after 14 daily treatments, a 3-fold 
reduction relative to initial tumor size was observed with a mean tumor volume of 38.4 ± 14.2 mm3 
Figure 2. Effect of MAG-EPA on HCT 16 cell proliferation and apoptosis in spheroid culture.
(a) V l e of c trol a -EP -tr ate s eroids, n = 15 for each experimental condition,
* . . ( ) r i t i l i i i it ff t f -EP s heroids proliferation
following Cyquant a say, n = 12 for each condition. (c) Cleaved caspases 3 and 7 signals in CT116
spheroids in control and following 48 h -EP tre t e t ( µ ). ree , c s se 7; blue,
nuclear DNA (DAPI). Bar 100 µ . (d) ean caspase 3 7 activity was determined using the cell event
fluoro etric assay on control and -EP -treated 116 spheroids, n = 12.
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tumor growth and reduce the size of the tumor observed prior o treatment (Figure 3a). M r over,
Mar. Drugs 2017, 15, 283 5 of 13
at day 13, the mean tumor volume was 101.7 ± 2.6 mm3, whereas after 14 daily treatments, a 3-fold
reduction relative to initial tumor size was observed with a mean tumor volume of 38.4 ± 14.2 mm3
at day 27. No significant difference in mice weight was found between groups. Representative
macroscopic images demonstrated the reduction of tumor size in MAG-EPA-treated mice compared to
control animals (Figure 3b). Caspase-3 activation assay was performed in order to identify the effect
of MAG-EPA treatment on the level of cleaved caspase-3 detected in tumor homogenates. Results
demonstrated that MAG-EPA induced a significant activation of caspase-3 in tumor tissue (Figure 3c)
compared with tumor homogenates derived from control mice.
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Figure 3. Effect of MAG-EPA treatment on tumor growth in the HCT116 xenograft nude mice model. 
(a) Tumor growth (mm3) as a function of time (day) was measured after subcutaneous injection of 1 × 
106 HCT116 cells in control and MAG-EPA (618 mg/kg)-treated mice. Results represent the mean 
volume ± SEM (n = 6 per group). (b) Representative macroscopic images of tumor size derived from 
control and MAG-EPA-treated mice. (c) Cleaved caspase-3 levels were determined using specific 
ELISA in tumor homogenates derived from control and MAG-EPA-treated mice, n = 6, * p < 0.05. 
2.4. Effect of MAG-EPA on VEGF, HIF1α and VEGFR Phosphorylation Level 
To determine whether MAG-EPA induced the reduction in the tumor formation and anti-cancer 
effects, the protein levels of VEGF and HIF1α, as well as the phosphorylation level of VEGFR were 
determined in tumors derived from control and MAG-EPA-treated animals. Figure 4a,b illustrate the 
representative western blot and quantitative analyses performed on tumor homogenates derived 
from control and MAG-EPA-treated mice using antibodies against VEGF, HIF1α, and β-actin. Results 
revealed that MAG-EPA treatments reduced VEGF and HIF1α expression levels in tumors when 
compared with the tumors derived from control mice (Figure 4a). Significant reductions of 64 ± 3.1% 
and 80 ± 4.2% were quantified for expression levels of VEGF and HIF1α in MAG-EPA-treated mice 
following a comparative analysis of VEGF/β-actin and HIF1α/β-actin ratios after the normalization 
of identical immunoblot membrane areas (Figure 4b). Western blot analyses using antibodies against 
total VEGFR and β-actin as well as phosphorylated forms of VEGFR (P-Y1059 and P-Y951) were 
performed on tumor homogenates derived from control and MAG-EPA-treated mice (Figure 4c). 
Results revealed that the MAG-EPA treatments decreased the phosphorylation levels of VEGFR in 
tumors comparatively to those observed in the control group (Figure 4c). Significant reductions of 
77% and 87% were quantified for phosphorylated levels of P-Y1059 and Y951 in MAG-EPA-treated 
mice following comparative analysis of P-VEGFR/total VEGFR ratio following the normalization of 
identical immunoblot membrane areas (Figure 4d). 
Figure 3. Effect of MAG-EPA treatment on tumor growth in the HCT116 xenograft nude mice model.
(a) Tumor growth (mm3) as a function of time (day) was measured after subcutaneous injection of
1 × 106 HCT116 cells in control and MAG-EPA (618 mg/kg)-treated mice. Results represent the mean
volume ± SEM (n = 6 per group). (b) Representative macroscopic images of tumor size derived from
control and MAG-EPA-treated mice. (c) Cleaved caspase-3 levels were determined using specific ELISA
in tumor homogenates derived from control and MAG-EPA-treated mice, n = 6, * p < 0.05.
2.4. Effect of MAG-EPA on VEGF, HIF1α and VEGFR Phosphorylation Level
To determine whether MAG-EPA induced the reduction in the tumor formation and anti-cancer
effects, the protein levels of VEGF and HIF1α, as well as the phosphorylation level of VEGFR were
determined in tumors derived from control and MAG-EPA-treated animals. Figure 4a,b illustrate
the representative western blot and quantitative analyses performed on tumor homogenates derived
from control and MAG-EPA-treated mice using antibodies against VEGF, HIF1α, and β-actin. Results
revealed that MAG-EPA treatments reduced VEGF and HIF1α expression levels in tumors when
compared with the tumors derived from control mice (Figure 4a). Significant reductions of 64 ± 3.1%
and 80 ± 4.2% were quantified for expression levels of VEGF and HIF1α in MAG-EPA-treated mice
following a comparative analysis of VEGF/β-actin and HIF1α/β-actin ratios after the normalization
of identical immunoblot membrane areas (Figure 4b). Western blot analyses using antibodies against
total VEGFR and β-actin as well as phosphorylated forms of VEGFR (P-Y1059 and P-Y951) were
performed on tumor homogenates derived from control and MAG-EPA-treated mice (Figure 4c).
Results revealed that the MAG-EPA treatments decreased the phosphorylation levels of VEGFR in
tumors comparatively to those observed in the control group (Figure 4c). Significant reductions of
77% and 87% were quantified for phosphorylated levels of P-Y1059 and Y951 in MAG-EPA-treated
mice following comparative analysis of P-VEGFR/total VEGFR ratio following the normalization of
identical immunoblot membrane areas (Figure 4d).
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Figure 4. Effect of MAG-EPA on HIF-1α and vascular endothelial growth factor (VEGF) expression 
and VEGFR2 phosphorylation levels in tumor homogenates. (a) Proteins from distinct homogenates 
were stained using specific antibodies against HIF-1α, VEGF and β-actin. (b) Quantitative analyses of 
mean HIF-1α/β-actin and VEGF/β-actin density ratios, (n = 6, * p < 0.05). (c) Western blot analysis of 
phosphorylated forms of VEGFR2, P-VEGFR (Y1059) and P-VEGFR (Y951), total VEGFR2 and β-actin 
protein detection (n = 6). (d) Quantitative analyses of P-VEGFR2/VEGFR2 mean density ratios, (n = 6, 
* p < 0.05). 
2.5. MAG-EPA Reduced EGFR and AKT Phosphorylation Levels in Tumor Tissues 
Western blot analyses were performed to assess the expression level of total and phosphorylated 
forms of EGFR in tumor homogenates derived from the control and MAG-EPA-treated mice. 
Analyses revealed a reduced EGFR phosphorylation level in tumor homogenates derived from MAG-
EPA-treated mice comparatively to control mice (Figure 5a). Moreover, a reduction of total EGFR 
protein expression was observed following the MAG-EPA treatment. β-actin staining remained 
constant under the experimental conditions (Figure 5a). Upon quantitative comparative analysis of 
the P-EGFR/EGFR ratio after normalization of identical immunoblot membrane areas (Figure 5b), 
results showed that MAG-EPA decreased the EGFR phosphorylation levels by 86% compared to the 
control group. Further experiments were also performed to evaluate the effect of MAG-EPA on AKT 
phosphorylation levels. Western blot analysis of tumor homogenates derived from these 
preparations revealed a reduction in AKT phosphorylation levels following MAG-EPA treatment 
when compared with control mice (Figure 5c), which translated into significant reductions of 80% 
and 71% in P-AKTser/AKT and P-AKTthr/AKT ratios, respectively, after the normalization of 
identical immunoblot membrane areas (Figure 5d). 
Figure 4. Effect of MAG-EPA on HIF-1α and vascular endothelial growth factor (VEGF) expression
and VEGFR2 phosphorylation levels in tumor homogenates. (a) Proteins from distinct homogenates
were stained using specific antibodies against HIF-1α, VEGF and β-actin. (b) Quantitative analyses of
mean HIF-1α/β-actin and VEGF/β-actin density ratios, (n = 6, * p < 0.05). (c) Western blot analysis of
phosphorylated forms of VEGFR2, P-VEGFR (Y1059) and P-VEGFR (Y951), total VEGFR2 and β-actin
protein detection (n = 6). (d) Quantitative analyses of P-VEGFR2/VEGFR2 mean density ratios, (n = 6,
* p < 0.05).
2.5. MAG-EPA Reduced EGFR and AKT Phosphorylation Levels in Tumor Tissues
Western blot analyses were performed to assess the expression level of total and phosphorylated
forms of EGFR in tumor homogenates derived from the control and MAG-EPA-treated mice.
Analyses revealed a reduced EGFR phosphorylation level in tumor homogenates derived from
MAG-EPA-treated mice comparatively to control mice (Figure 5a). Moreover, a reduction of total
EGFR protein expression was observed following the MAG-EPA treatment. β-actin staining remained
constant under the experimental conditions (Figure 5a). Upon quantitative comparative analysis of
the P-EGFR/EGFR ratio after normalization of identical immunoblot membrane areas (Figure 5b),
results showed that MAG-EPA decreased the EGFR phosphorylation levels by 86% compared to
the control group. Further experiments were also performed to evaluate the effect of MAG-EPA
on AKT phosphorylation levels. Western blot analysis of tumor homogenates derived from these
preparations revealed a reduction in AKT phosphorylation levels following MAG-EPA treatment
when compared with control mice (Figure 5c), which translated into significant reductions of 80% and
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71% in P-AKTser/AKT and P-AKTthr/AKT ratios, respectively, after the normalization of identical
immunoblot membrane areas (Figure 5d).Mar. Drugs 2017, 15, 283 7 of 13 
 
 
Figure 5. Effect of MAG-EPA on phosphorylation state of EGFR in tumor homogenates. (a) Western 
blot analysis of tumor homogenate protein fractions derived from control and MAG-EPA-treated 
mice, using specific antibodies against phosphorylated form of EGFR, total EGFR, and β-actin. (b) 
Quantitative analysis of P-EGFR/EGFR density ratios as a function of experimental conditions (n = 6, 
* p < 0.05). (c) Western blot analysis of phosphorylated forms of AKT (P-AKTser, P-AKTthr) and total 
AKT protein detection (n = 6). (d) Quantitative analyses of P-AKT/AKT mean density ratios, (n = 6, * 
p < 0.05). 
2.6. Comparative Effects of Krill Oil, EPA-EE and MAG-EPA Treatment on HCT116-Induced Tumor 
Formation 
An in vivo nude mice HCT116 xenograft model was used to compare the ability of MAG-EPA 
to reduce tumor formation vs Krill oil and EPA-EE. Following the formation of 100 mm3 tumors, mice 
were randomly divided into three groups at day 13, namely Krill oil, EPA-EE, and MAG-EPA-treated. 
Krill oil, EPA-EE, and MAG-EPA were administered daily per os in pharmacological dose (618 mg/kg 
total omega-3), corresponding to a daily dose of 3.0 g/day total omega-3 for human [10]. Krill oil and 
EPA-EE treatments slightly reduced tumor latency and growth when compared to control mice- from 
a previous experiment (Figure 3). No significant reductions of tumor growth were quantified in Krill 
oil and EPA-EE groups (Figure 6). In contrast, MAG-EPA treatment resulted in a significant reduction 
of tumor growth when compared to Krill oil or EPA-EE groups (Figure 6). Of note, no significant 
difference in mice weight was observed between groups. Table 1 illustrates the fatty acids 
composition of the marine omega-3 oils used for treated mice. 
Figure 5. Effect of MAG-EPA on phosphorylation state of EGFR in tumor homogenates. (a) Western blot
analysis of tumor homogenate protein fractions derived from control and MAG-EPA-treated mice, using
specific antibodies against phosphorylated form of EGFR, total EGFR, and β-actin. (b) Quantitative
analysis of P-EGFR/EGFR density ratios as a function of experimental conditions (n = 6, * p < 0.05).
(c) Western blot analysis of phosphorylated forms of AKT (P-AKTser, P-AKTthr) and total AKT protein
detection (n = 6). (d) Quantitative analyses of P-AKT/AKT mean density ratios, (n = 6, * p < 0.05).
2.6. Comparative Effects of Krill Oil, EPA-EE and MAG-EPA Treatment on HCT116-Induced
Tumor Formation
An in vivo nude mice HCT116 xenograft model was used to compare the ability of MAG-EPA to
reduce tumor formation vs Krill oil and EPA-EE. Following the formation of 100 mm3 tumors, mice
were randomly divided into three groups at day 13, namely Krill oil, EPA-EE, and MAG-EPA-treated.
Krill oil, EPA-EE, and MAG-EPA were administered daily per os in pharmacological dose (618 mg/kg
total omega-3), corresponding to a daily dose of 3.0 g/day total omega-3 for human [10]. Krill oil and
EPA-EE treatments slightly reduced tumor latency and growth when compared to control mice- from
a previous experiment (Figure 3). No significant reductions of tumor growth were quantified in Krill
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oil and EPA-EE groups (Figure 6). In contrast, MAG-EPA treatment resulted in a significant reduction
of tumor growth when compared to Krill oil or EPA-EE groups (Figure 6). Of note, no significant
difference in mice weight was observed between groups. Table 1 illustrates the fatty acids composition
of the marine omega-3 oils used for treated mice.Mar. Drugs 2017, 15, 283 8 of 13 
 
 
Figure 6. Effect of EPA-EE and Krill oil treatment on tumor growth in the HCT116 xenograft nude 
mice model. Tumor growth (mm3) as a function of time (day) was measured after subcutaneous 
injection of 1 × 106 HCT116 cells in EPA-EE (618 mg/kg), Krill oil (618 mg/kg) and MAG-EPA  
(618 mg/kg)-treated mice. Compounds were administered orally daily dose of 618 mg/kg total  
omega-3 from day 13 to day 27. Results represent the mean volume ± SEM (n = 6 per group, * p < 0.05). 
Table 1. Fatty acids composition of the marine omega-3 oils. DHA, EPA, and total omega-3 contents 
were reported in mg/g for Krill oil, EPA-EE, and MAG-EPA. 
3.0 g/Day Total Omega-3 Human Equivalent EPA (mg/g) DHA (mg/g) Total Omega-3 (mg/g)
MAG-EPA 819 39 888 
EPA-EE 724 104 930 
Krill Oil (3X volume) 150 90 300 
3. Discussion 
In the present study, MAG-EPA was found to reduce cell proliferation and to induce apoptosis 
of HCT116 colorectal carcinoma cells. These effects of MAG-EPA in an in-vitro model and an in-vivo 
mouse xenograft model were correlated with a reduction in phosphorylation levels of VEGFR, EGFR 
and total VEGF and HIF1α protein expressions as well as an enhanced apoptosis leading to a 
reduction in tumor cell proliferation. 
3.1. MAG-EPA Decreases Cell Proliferation and Induces Apoptosis of Colorectal Carcinoma Cells 
Previously, we and others showed that PUFAs, especially EPA, DHA, and DPA have an 
inhibitory effect on the growth of tumor cells both in vitro and in vivo with no cytotoxic action on 
normal cells [8,11–15]. Tumor cells are known to be deficient in the activity of Δ6 and Δ5 desaturases 
[16], and thus, may contain substantially lower amounts of EPA and DHA compared to normal cells. 
Consequently, low amounts of PUFAs in tumor cells may trigger to augment prostaglandins and 
leukotrienes synthesis as a compensatory mechanism [11]. PGE2 and PGF2α as well as LTA4 and 
LTB4 are known to be produced in significantly higher amounts by tumor cells, which may enhance 
their motility and invasive capacity [17,18]. In contrast, PUFAs give rise to potent anti-inflammatory 
molecules LXs, resolvins, protectins, maresins, and nitrolipids [19,20]. These anti-inflammatory 
molecules, especially resolvins and protectins have a direct growth inhibitory action on tumor cells 
[19,21]. Our in vivo results clearly indicate that MAG-EPA was more potent than an equivalent dose 
of omega-3 in ethyl esters form (EPA-EE) or phospholipids/free fatty acids form (Krill oil) to inhibit 
tumor growth in mice bearing human colon cancer xenografts. Moreover, when administered orally 
Figure 6. Effect of EPA-EE and Krill oil treatment on tumor growth in the HCT116 xenograft nude mice
model. Tumor growth (mm3) as a function of time (day) was measured after subcutaneous injection of
1 × 106 HCT116 cells in EPA-EE (618 mg/kg), Krill oil (618 mg/kg) and MAG-EPA (618 mg/kg)-treated
mice. Compounds were administered orally daily dose of 618 mg/kg total omega-3 from day 13 to day
27. Results represent the mean volume ± SEM (n = 6 per group, * p < 0.05).
Table 1. Fatty acids composition of the marine omega-3 oils. DHA, EPA, and total omega-3 contents
were reported in mg/g for Krill oil, EPA-EE, and MAG-EPA.
3.0 g/Day Total Omega-3 Human Equivalent EPA (mg/g) DHA (mg/g) Total Omega-3 (mg/g)
MAG-EPA 819 39 888
EPA-EE 724 104 930
Krill Oil (3X volume) 150 90 300
3. Discussion
In the present study, MAG-EPA was found to reduce cell proliferation and to induce apoptosis of
HCT116 colorectal carcinoma cells. These effects of MAG-EPA in an in-vitro model and an in-vivo
mouse xenograft model were correlated with a reduction in phosphorylation levels of VEGFR, EGFR
and total VEGF and HIF1α protein expressions as well as an enhanced apoptosis leading to a reduction
in tumor cell proliferation.
3.1. MAG-EPA Decreases Cell Proliferation and Induces Apoptosis of Colorectal Carcinoma Cells
Previously, we and others showed that PUFAs, especially EPA, DHA, and DPA have an inhibitory
effect on the growth of tumor cells both in vitro and in vivo with no cytotoxic action on normal
cells [8,11–15]. Tumor cells are known to be deficient in the activity of ∆6 and ∆5 desaturases [16],
and thus, may contain substantially lower amounts of EPA and DHA compared to normal cells.
Consequently, low amounts of PUFAs in tumor cells may trigger to augment prostaglandins and
leukotrienes synthesis as a compensatory mechanism [11]. PGE2 and PGF2α as well as LTA4 and
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LTB4 are known to be produced in significantly higher amounts by tumor cells, which may enhance
their motility and invasive capacity [17,18]. In contrast, PUFAs give rise to potent anti-inflammatory
molecules LXs, resolvins, protectins, maresins, and nitrolipids [19,20]. These anti-inflammatory
molecules, especially resolvins and protectins have a direct growth inhibitory action on tumor
cells [19,21]. Our in vivo results clearly indicate that MAG-EPA was more potent than an equivalent
dose of omega-3 in ethyl esters form (EPA-EE) or phospholipids/free fatty acids form (Krill oil) to
inhibit tumor growth in mice bearing human colon cancer xenografts. Moreover, when administered
orally in a therapeutic mode in mice, MAG-EPA was found to inhibit the growth, and reduced the
size of tumors by up to 75% in comparison to tumor size prior to treatment. These observations
have clinical relevance since it has been shown that the ratio of dietary ω-6 to ω-3 PUFA is one of
the most important factors in determining the cancer risk relative to fatty acid intake [22]. Similarly,
another study has demonstrated that the dietary administration of one or both of the main n-3 PUFA
in rodent models of colorectal carcinogenesis reduced colorectal tumor size and multiplicity [8,23].
In a population-based prospective study on the association of omega-3 PUFA and cancer, there was
an inverse relationship between marine omega-3 PUFA intake and the risk of colorectal cancer [24].
The excellent tolerability and safety profile of omega 3 PUFAs combined with other health benefits,
particularly cardiovascular, make MAG-EPA an attractive candidate for prevention and treatment
of CRC.
3.2. MAG-EPA Decreases VEGFR and EGFR Activation Pathways in Colorectal Carcinoma Cells
In an attempt to understand the mechanism by which MAG-EPA mediates its antitumor effects
in colorectal cancer cells, we determined whether this monoglyceride form of omega-3 modulates
VEGFR and EGFR signaling pathways in tumor homogenates derived from control (untreated) and
MAG-EPA-treated mice. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor
associated with tumor progression and metastasis in numerous solid malignancies [25]. VEGF binds
to three tyrosine kinase receptors: VEGFR-1, VEGFR-2, and VEGFR-3 [25]. Studies have shown
VEGFR-2 to be expressed on tumor cells and to be implicated in tumor growth and progression,
including activation of the Erk-1/2 and AKT and MAPK pathways [26–28]. Moreover, studies have
shown that antiangiogenic therapy targeting the tyrosine kinase receptor for the VEGF receptor
inhibits the vascularity, proliferation, and growth of colon cancer liver metastasis and significantly
increases endothelial and tumor cell apoptosis [25]. In the xenograft model herein, we found that
MAG-EPA downregulated the phosphorylated form of VEGFR in tumor when compared to control
mice. Moreover, MAG-EPA treatment also slightly reduced VEGFR expression in HCT116 tumors.
The epidermal growth factor receptor (EGFR) is recognized as an important player in colorectal
cancer (CRC) initiation and progression [29]. Overexpression of EGFR is common in many tumors.
Specifically in CRC, EGFR it is estimated to be overexpressed in 60–80% of tumors, and is associated
with a poor prognosis [29]. For these reasons EGFR has been targeted for treatment with small molecule
inhibitors and monoclonal antibodies. EGFR is a multifunctional receptor that plays a key role in cell
division and apoptosis, cell differentiation and dedifferentiation, and migration [30]. EGFR executes
these functions by the activation of multiple signaling pathways including PLC-gamma-1, MAPKs,
AKT, JNK and the signal transducers and activators of transcription [30]. HCT116 cells express high
levels of EGFR and are a good model to study EGFR modulation by MAG-EPA. We found that the
phosphorylated EGFR levels are reduced after treatment with MAG-EPA in tumor derived from
HCT116 xenograft mice model when compared to the tumors derived from untreated control animals.
Moreover, MAG-EPA treatment also slightly reduced EGFR concentration in HCT116 tumors. Similarly,
a study has shown a reduction of EGFR activation in EPA- or DHA-induced apoptosis in breast cancer
(MDA-MB-231 and MCF-7) cells, associated to a reduction of Bcl2 and caspase-8 expression [31].
The entire mechanism by which MAG-EPA exert their beneficial effects is not fully understood.
However, we have hypothesized that the induction of apoptosis and the reduction of HCT116 cell
proliferation induced by MAG-EPA might be explained by a reduced activation of the VEGFR and
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EGFR pathways, which is correlated with a downregulation of AKT signaling in tumor homogenates.
Moreover, MAG-EPA treatment activated the caspase-3, which resulted in an increased number of
apoptotic cells in tumor tissues, in agreement with previous studies in which supplementation with
fish oil [32] or EPA/DHA [33] significantly inhibited the growth of xenografted tumors in mouse
models at a high dose (equivalent to 30 g/day in humans). Further experiments are needed to elucidate
whether MAG-EPA induce apoptosis by targeting intrinsic and/or extrinsic pathway.
4. Conclusions
In the present study, MAG-EPA may promote apoptosis and inhibit growth of tumors by
suppressing EGFR and VEGFR activation pathways, as well as the production of VEGF and HIF1α.
Moreover, we and others have recently demonstrated that the anti-proliferative and pro-apoptotic
actions of the MAG-EPA compound may partially be explained by the inhibition of signaling
pathways including NF-κB, EGFR, VEGFR, and AKT, and the down regulation of its gene products.
In consequence, we and others suggests that a balance between pro-inflammatory molecules (PGs, LTs,
and TXs) and anti-inflammatory PUFAs-derived molecules (resolvins, protectins) may determine the
degree of proliferation and invasive capacity of tumor cells [8,19]. With our current knowledge, we are
not able to predict specific PUFA potency, and for future clinical applications, a screening of several
PUFA directly on tumor tissue or on isolated circulating tumor cells (CTCs) could be the only way to
find the best PUFA for specific cancers.
5. Materials and Methods
5.1. Marine Omega-3 Oils
MAG-EPA (Solutex, Madrid, Spain) is a fish oil concentrate in monoglycerides form containing
819 mg/g EPA and 39 mg/g DHA. EPA-EE (Equateq Ltd., Isle of Lewis, UK) is a fish oil concentrate in
ethyl esters form containing 724 mg/g EPA and 104 mg/g DHA. Krill oil (Jedwards International Inc.,
Braintree, MA, USA) is an oil in phospholipids and free fatty acids form containing 150 mg/g EPA and
90 mg/g DHA.
5.2. Cell Line and Culture
Human HCT116 colorectal adenocarcinoma cells were obtained from the American Type Culture
Collection (ATCC). HCT116 cells were maintained in McCoy’s 5A medium (Wisent, St-Bruno, QC,
Canada) containing 10% FBS, 5 mM HEPES, and 10 units/mL penicillin, 100 µg/mL streptomycin.
Cells were grown in a 5% CO2 incubator at 37 ◦C. Cells were used between passage 3 to 6 for all
conditions and assays tested in this study. Cells were untreated or treated with MAG-EPA at the
indicated concentrations (0.03–100 µM). MAG-EPA was dissolved in 100% ethanol and diluted to a
final concentration of 0.1% ethanol. Cell proliferation analyses were performed using the BrdU cell
proliferation assay kit according to the manufacturer’s instructions (New England BioLabs, Pickering,
ON, Canada). This kit detects the level of 5-bromo-2’-deoxyuridine (BrdU) incorporated into cellular
DNA during cell proliferation using an anti-BrdU antibody. Apoptosis analyses were performed
using (1) a terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay
in accordance with the manufacturer’s instructions (EMD Millipore, Bellerica, MA, USA) and (2) a
cleaved caspase-3 ELISA assay according to the manufacturer’s instructions (New England BioLabs,
Pickering, ON, Canada) [8].
5.3. Spheroids
Human HCT116 colorectal adenocarcinoma cells were cultured in Perfecta3D 96-well hanging
drop plate, according to the manufacturer’s instructions (3D Biomatrix Inc., Ann Arbor, MI, USA).
Hanging drops were formed using a cell suspension of 5000 cells/well in McCoy’s 5A medium (Wisent,
St-Bruno, QC, Canada) containing 10% FBS and 5 mM HEPES. Spheroids were grown in a 5% CO2
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incubator at 37 ◦C during 3 weeks. Every day for each well, 10 µL of media was removed and replaced
by 14 µL of fresh media. Spheroids were treated directly in wells with final concentrations of MAG-EPA
of 1 µM, 3 µM, 10 µM, and 30 µM. Cells proliferation analyses in spheroids were performed using
Cyquant assay kit according to the manufacturer’s instructions (Life technologies, Eugene, OR, USA).
Immunofluorescence and apoptosis analyses on HCT116 spheroids were performed using Cell event
caspase 3/7 assay kit according to the manufacturer’s instructions (Life technologies, Eugene, OR,
USA). Image analyses were performed for immunopositive pixel staining of cleaved caspase 3/7 in
spheroids sections using an inverted epifluorescence microscope (Nikon-Canada, Mississauga, ON,
Canada) and MetaMorph 7.6 software (Molecular Devices, Sunnyvale, CA, USA). DAPI was used
as counterstaining.
5.4. In Vivo Tumor Xenograft Experiments
Female nu/nu nude mice were obtained from Charles River Laboratories (Montreal, QC, Canada).
All studies involving mice were approved by the institutional Animal Care Committee (Protocol:
# 237-10). Human HCT116 xenografts were established in 4-week-old nude mice. Mice were
subcutaneously inoculated with 0.2 mL of 1× 106 HCT116 cells in McCoy’s 5A on the right flank. After
the formation of 100 mm3 tumors, mice were randomly assigned into 4 groups, control (untreated),
MAG-EPA-treated (n = 8 per group), Krill-Oil-treated, and EPA-EE (ethyl ester)-treated. MAG-EPA
was administered per os (618 mg/kg) daily. Krill oil and EPA-EE were administered per os at a human
equivalent of 3.0 g/day of total omega-3. Tumor volumes (V) were calculated using the formula:
V = (a × b2)/2, where “a” is the largest superficial diameter and “b” the smallest. Cleaved caspase-3
ELISA assay was performed on tumor homogenate derived from the control and treated mice according
to the manufacturer’s instructions (New England BioLabs, Pickering, ON, Canada). Western blot
analyses using specific antibodies against phosphorylated forms of VEGFR (Y1059 and Y951), EGFR,
and AKT (at serine and threonine residues) as well as total form of VEGFR, EGFR, AKT, β-actin,
VEGF and HIF1αwere performed on tumor homogenates derived from control and MAG-EPA-treated
mice [8,15].
5.5. Data Analysis and Statistics
Results are expressed as means ± S.E.M., with n indicating the number of experiments. Statistical
analyses were performed using Sigma Plot 11 and SPSS 14.0 (SPSS-Science, Chicago, IL, USA) via
one-way ANOVA followed by Dunnett’s post-hoc test. Differences were considered statistically
significant * when p < 0.05.
Acknowledgments: The MAG-EPA has been kindly donated by Solutex (Spain).
Author Contributions: Caroline Morin, Pierre U. Blier and Samuel Fortin conceived the study, and participated in
its design and coordination and commented on the draft version of the paper. Samuel Fortin, Enrique Rodríguez
and Caroline Morin contributed to data collection, conducted the analysis, wrote the paper and managed the
overall project. All authors read and approved the final manuscript.
Conflicts of Interest: The authors declare no conflict of interest. Samuel Fortin is the owner of SCF Pharma,
which has an exclusive worldwide license of the patented uses of MAG-EPA.
References
1. Dyerberg, J.; Madsen, P.; Møller, J.M.; Aardestrup, I.; Schmidt, E.B. Bioavailability of marine n-3 fatty acid
formulations. Prostaglandins Leukot. Essent. Fat. Acids 2010, 83, 137–141. [CrossRef] [PubMed]
2. Geelen, A.; Schouten, J.M.; Kamphuis, C.; Stam, B.E.; Burema, J.; Renkema, J.M. Fish consumption, n-3 fatty
acids, and colorectal cancer: A meta-analysis of prospective cohort studies. Am. J. Epidemiol. 2007, 166,
1116–1125. [CrossRef] [PubMed]
3. Simopoulos, A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21,
495–505. [CrossRef] [PubMed]
Mar. Drugs 2017, 15, 283 12 of 13
4. Hall, M.N.; Campos, H.; Li, H.; Sesso, H.D.; Stampfer, M.J.; Willett, W.C. Blood levels of long-chain
polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2007,
16, 314–321. [CrossRef] [PubMed]
5. Cruz-Hernandez, C.; Thakkar, S.K.; Moulin, J.; Oliveira, M.; Masserey-Elmelegy, I.; Dionisi, F.; Destaillats, F.
Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipid
malabsorption. Nutrients 2012, 4, 1781–1793. [CrossRef] [PubMed]
6. Fortin, S. Polyunsaturated Fatty Acid Monoglycerides, Derivatives, and Uses Thereof. U.S. Patent 8,119,690
B2, 21 February 2012.
7. Fortin, S. Compositions Comprising Polyunsaturated Fatty Acid Monoglycerides or Derivatives Thereof and
Uses Thereof. U.S. Patent 8,222,295 B2, 17 July 2012.
8. Morin, C.; Rousseau, É.; Fortin, S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride
in colorectal carcinoma cells. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 203–213. [CrossRef] [PubMed]
9. Parkin, D.M.; Olsen, A.H.; Sasieni, P. The potential for prevention of colorectal cancer in the UK. Eur. J.
Cancer Prev. 2009, 18, 179–190. [CrossRef] [PubMed]
10. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J.
2008, 22, 659–661. [CrossRef] [PubMed]
11. Chen, Z.Y.; Istfan, N.W. Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells.
Prostaglandins Leukot. Essent. Fat. Acids 2000, 63, 301–308. [CrossRef] [PubMed]
12. Dai, J.F.; Shen, J.H.; Pan, W.S.; Shen, S.R.; Das, U.N. Effects of polyunsaturated fatty acids on the growth of
gastric cancer cells in vitro. Lipids Health Dis. 2013, 12, 71. [CrossRef] [PubMed]
13. Fasano, E.; Serini, S.; Piccioni, E.; Toesca, A.; Monego, G.; Cittadini, A.R.; Ranelletti, F.O.; Calviello, G.
DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines.
Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2012, 1822, 1762–1772. [CrossRef] [PubMed]
14. Lu, X.; Yu, H.; Ma, Q.; Shen, S.; Das, U.N. Linoleic acid suppresses colorectal cancer cell growth by inducing
oxidant stress and mitochondrial dysfunction. Lipids Health Dis. 2010, 9, 106. [CrossRef] [PubMed]
15. Morin, C.; Fortin, S.; Cantin, A.M.; Sirois, M.; Sirois, C.; Rizcallah, E.; Rousseau, É. Anti-cancer effects of a
new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat. Anticancer Drug Discov.
2013, 8, 319–334. [CrossRef] [PubMed]
16. Das, U.N. Essential fatty acids enhance free radical generation and lipid peroxidation to induce apoptosis of
tumor cells. Clin. Lipidol. 2011, 6, 463–489. [CrossRef]
17. Chen, E.P.; Smyth, E.M. COX-2 and PGE2-dependent immunomodulation in breast cancer.
Prostaglandins Other Lipid Mediat. 2011, 96, 14–20. [CrossRef] [PubMed]
18. Qualtrough, D.; Kaidi, A.; Chell, S.; Jabbour, H.N.; Williams, A.C.; Paraskeva, C. Prostaglandin F(2α)
stimulates motility and invasion in colorectal tumor cells. Int. J. Cancer 2007, 121, 734–740. [CrossRef]
[PubMed]
19. Das, U.N. Lipoxins, resolvins, protectins, maresins and nitrolipids, and their clinical implications with
specific reference to cancer: part I. Clin. Lipidol. 2013, 8, 437–463. [CrossRef]
20. Serhan, C.N.; Arita, M.; Hong, S.; Gotlinger, K. Resolvins, docosatrienes, and neuroprotectins, novel
omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004, 39, 1125–1132.
[CrossRef] [PubMed]
21. Sailaja, P.; Mani, A.M.; Naveen, K.V.G.; Anasuya, D.H.; Siresha, B.; Das, U.N. Effect of polyunsaturated fatty
acids and their metabolites on bleomycin-induced cytotoxic action on human neuroblastoma cells in vitro.
PLoS ONE 2014, 9, e114766.
22. Okuyama, H.; Kobayashi, T.; Watanabe, S. Dietary fatty acids—The n-6/n-3 balance and chronic elderly
diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Prog. Lipid Res. 1996, 35,
409–457. [CrossRef]
23. Latham, P.; Lund, E.K.; Johnson, I.T. Dietary n-3 PUFA increases the apoptotic response to
1,2-dimethylhydrazine, reduces mitosis and suppresses the induction of carcinogenesis in the rat colon.
Carcinogenesis 1999, 20, 645–650. [CrossRef] [PubMed]
24. Park, J.M.; Kwon, S.H.; Han, Y.M.; Hahm, K.B.; Kim, E.H. Omega-3 Polyunsaturated Fatty Acids as Potential
Chemopreventive Agent for Gastrointestinal Cancer. J. Cancer Prev. 2013, 18, 201–208. [CrossRef] [PubMed]
25. Niu, G.; Chen, X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
Curr. Drug Targets 2010, 11, 1000–1017. [CrossRef] [PubMed]
Mar. Drugs 2017, 15, 283 13 of 13
26. La Rosa, S.; Uccella, S.; Finzi, G.; Albarello, L.; Sessa, F.; Capella, C. Localization of vascular endothelial
growth factor and its receptors in digestive endocrine tumors: Correlation with microvessel density and
clinicopathologic features. Hum. Pathol. 2003, 34, 18–27. [CrossRef] [PubMed]
27. Masood, R.; Cai, J.; Zheng, T.; Smith, D.L.; Hinton, D.R.; Gill, P.S. Vascular endothelial growth factor (VEGF) is
an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98, 1904–1913. [CrossRef]
[PubMed]
28. Von Marschall, Z.; Cramer, T.; Höcker, M.; Burde, R.; Plath, T.; Schirner, M.; Heidenreich, R.; Breier, G.;
Riecken, E.O.; Wiedenmann, B.; et al. De novo expression of vascular endothelial growth factor in human
pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 2000, 119, 1358–1372. [CrossRef]
[PubMed]
29. Cohen, R.B. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.Clin. Colorectal Cancer
2003, 2, 246–251. [CrossRef] [PubMed]
30. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31, 637–643. [CrossRef]
31. Corsetto, P.A.; Montorfano, G.; Zava, S.; Jovenitti, I.E.; Cremona, A.; Berra, B.; Rizzo, A.M. Effects of n-3
PUFAs on breast cancer cells through their incorporation in plasma membrane. Lipids Health Dis. 2011, 10, 73.
[CrossRef] [PubMed]
32. Yam, D.; Peled, A.; Shinitzky, M. Suppression of tumor growth and metastasis by dietary fish oil combined
with vitamins E and C and cisplatin. Cancer Chemother. Pharmacol. 2001, 47, 34–40. [CrossRef] [PubMed]
33. De Bravo, M.G.; De Antueno, R.J.; Toledo, J.; De Tomas, M.E.; Mercuri, O.F.; Quintans, C. Effects of an
eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice.
Lipids 1991, 26, 866–870. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
